GeoVax Labs, Inc. Email Format
Biotechnology ResearchGeorgia, United States11-50 Employees
GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines using a platform based on Modified Vaccinia Ankara and virus-like particles. Its development programs cover vaccines for COVID-19 and a range of infectious diseases, including Ebola, Lassa, Marburg, malaria, Zika, and HIV, along with cancer immunotherapies targeting tumor-associated antigens such as MUC1 and HPV-related cancers. As of 2026, the company is advancing a GEO-MVA program toward Phase III trials to protect against mpox and smallpox. The company is headquartered in Smyrna, Georgia, and operates as a small to mid-sized biotechnology firm focused on infectious disease vaccines and cancer immunotherapies. Recent expansion moved its facilities to the Atlanta metropolitan area in 2025, reflecting ongoing development of its multi-antigen vaccine and immunotherapy portfolio.